Shares of GSK PLC GSK inched down 0.51% to £13.57 Friday, on what proved to be an all-around poor trading session for the ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

GSK plc GSK announced that the European Commission has granted approval for the expanded use of Jemperli (dostarlimab) plus ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

Is the frenzy of JPM dealmaking finally underway? GSK announced Monday morning that it will acquire the privately-held ...

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

The British pharma giant announced plans to acquire IDRx, a Plymouth-based biotech working on precision treatments for ...

Bullish option flow detected in GSK (GSK) Pharma with 3,057 calls trading, 1.1x expected, and implied vol increasing over 4 points to 29.80%. Feb-25 34 calls and 1/31 weekly 34 calls are the most ...

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...

The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.

Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...

J&J announces a big deal to acquire neuroscience company ITCI for $14.6 billion, while Lilly and GSK announce smaller deals.